360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Bosentan

Type: Product

Name: Bosentan

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Gilead Sciences Inc

Gilead Sciences, Inc. (GILD): The Heart Of The Matter

Gilead Sciences, Inc. (NASDAQ: GILD ) has exploded over the last few years as a powerhouse of anti-viral medications. Its myriad treatments for HIV have brought in $2 billion in Q1 alone , and its hepatitis C drug Sofosbuvir recently showed phenomenal ... [Published InsiderMonkey.com - May 08 2013]

Entities: Letairis, Gilead Sciences Inc, Bosentan, Adcirca

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Actelion Pharmaceuticals Ltd

UPDATE 1-Actelion gets go-ahead to continue new drug trial

* Selexipag is new drug for pulmonary arterial hypertension* Final results due by mid 2014* Actelion looking for alternatives to main drug Tracleer (Adds details, background)ZURICH, May 8 (Reuters) - Actelion should continue a late-stage study into a ... [Published Reuters - May 08 2013]

Entities: Actelion Pharmaceuticals Ltd, Pulmonary Arterial Hypertension, Drugs

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

United Therapeutic's Second PAH Stumble Emphasizes The Need For Pluristem's Therapy

United Therapeutics Corp. (UTHR), pharmaceutical partner to Pluristem Therapeutics (PSTI), needs now more than ever a way to compete in the elusive but growing worldwide market for pulmonary arterial hypertension (PAH), or high blood pressure in the lungs. ... [Published Seeking Alpha - Apr 30 2013]

Entities: Pulmonary Arterial Hypertension, Remodulin, Drugs, Gilead Sciences Inc, Opsumit

First reported Apr 18 2013 - Updated Apr 18 2013 - 4 reports

Jean-Pierre Garnier

ACTELION LTD: Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland

The meeting was attended by 272 shareholders. A total of 60'550'649 shares or 47.76% of the total outstanding shares were represented.Lead by the Chairman of the Board, Jean-Pierre Garnier, the company presented a review of the company's 2012 performance. ... [Published 4 Traders - Apr 18 2013]

Entities: Actelion Pharmaceuticals Ltd, Basel (Switzerland), Switzerland, Jean-Pierre Garnier, Allschwil (Switzerland)

First reported Apr 16 2013 - Updated Apr 16 2013 - 2 reports

Actelion delivers strong first quarter 2013 results Thomson Reuters ONE

- Actelion Ltd (ATLN.VX) today announced financial results for the first quarter of 2013. As of 31 March 2013, Actelion had cash and cash deposits of CHF 1.6 billion (of which CHF 628 million is restricted). In addition, Actelion holds 14 million treasury ... [Published Yahoo! Finance - Apr 16 2013]

Entities: Actelion Pharmaceuticals Ltd, Epoprostenol, Bosentan, Pulmonary Arterial Hypertension

First reported Apr 15 2013 - Updated Apr 16 2013 - 2 reports

H Lundbeck AS

Drug Makers Use Safety Rule to Block Generics New York Times

For decades, pharmaceutical companies have deployed an array of tactics aimed at preventing low-cost copies of their drugs from entering the marketplace.But federal regulators contend the latest strategy — which relies on a creative interpretation of ... [Published Yahoo! Finance - Apr 16 2013]

Entities: Drugs, Apotex, H Lundbeck AS, Actelion Pharmaceuticals Ltd, Gilead Sciences Inc

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Actelion Rises to Two-Year High as Company May Raise Forecast

April 16 (Bloomberg) -- Actelion Ltd., the Swiss drugmaker that gets most of its sales from one drug, rose to the highest in more than two years after saying it may raise its full-year forecast and reporting first-quarter profit that beat estimates.Actelion ... [Published Washington Post - Apr 16 2013]

Entities: Actelion Pharmaceuticals Ltd, Opsumit, Bosentan

First reported Apr 16 2013 - Updated Apr 16 2013 - 2 reports

ROUNDUP: Actelion May Boost Annual Profit Forecast After Q1 Net Income Surges

WASHINGTON (dpa-AFX) - Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) Tuesday reported significant growth in first-quarter profit, adding that it might raise its full year profit guidance.Andrew Oakley, Chief Financial Officer, said: 'We have delivered ... [Published FinanzNachrichten.de - Apr 16 2013]

Entities: Actelion Pharmaceuticals Ltd, Boost, Operating Income, Bosentan

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Actelion first-quarter net profit beats expectations

6:17am BSTZURICH, April 16 (Reuters) - Europe's largest biotech company Actelion said it expected to publish an interim analysis of late-stage data for its heart and lung drug selexipag in coming weeks, as net profit in the first-quarter beat expecta ... [Published Reuters UK - Apr 16 2013]

Entities: Actelion Pharmaceuticals Ltd, Net Profit, Pulmonary Arterial Hypertension, Bosentan

First reported Mar 12 2013 - Updated Mar 13 2013 - 2 reports

FTC Slams Drugmaker For Withholding Samples

Should a brand-name drugmaker be required to sell samples of its medicine to an aspiring generic rival when its medicine was approved with a Risk Evaluation and Mitigation Strategy? What if the brand-name drugmaker argues that its REMS could be threatened ... [Published Pharmalot - Mar 13 2013]

Entities: Actelion Pharmaceuticals Ltd, Bosentan, Apotex, Drugs

First reported Feb 27 2013 - Updated Feb 27 2013 - 1 reports

Orphan designation: Bosentan, for the: Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

[Published Orphan designations - Feb 27 2013]

Entities: Bosentan, Pulmonary Arterial Hypertension, Pulmonary Hypertension

First reported Dec 19 2012 - Updated Dec 20 2012 - 2 reports

TRACLEER (Bosentan) Tablet, Film Coated [Actelion Pharmaceuticals US, Inc.]

Updated Date: Dec 19, 2012 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Dec 20 2012]

Entities: Bosentan, US Inds Inc, Actelion Pharmaceuticals Ltd

Quotes

As a supplement to the ATS conference Actelion will host a symposium with Richard Channick, MD. The program entitled: "Emerging Developments and Insights in Pulmonary Arterial Hypertension: How We Think, How We Practice." will be hosted at Millennium Hall, Loews Philadelphia Hotel on Tuesday 21 May between 18:30 and 21:00

Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS (Actelio ... [Published Presscontacts.com - May 17 2013]

"The data provide a basis for explicit guidance to clinicians not to use ambrisentan to treat patients with IPF, regardless of the presence of pulmonary hypertension" they wrote

Ambrisentan Fails in Lung Fibrosis [Published MedPage Today - May 06 2013]

Andrew Oakley, Chief Financial Officer, said: "We have delivered a strong start to 2013. With the preparation of two Phase III studies underway and a product launch ahead, we will carefully look at guidance for the full year as it is possible that some of the forecasted profit growth for 2014 could be brought forward into this year."

ROUNDUP: Actelion May Boost Annual Profit Forecast After Q1 Net Income Surges [Published FinanzNachrichten.de - Apr 16 2013]

..." Andrew Oakley, Chief Financial Officer, fügte hinzu: "Wir haben das Jahr 2013 mit starken Ergebnissen begonnen. Angesichts der Vorbereitungen für zwei Phase-III-Studien und einer bevorstehenden Produkteinführung werden wir die Guidance für das Gesamtjahr nochmals genau überprüfen, da die Möglichkeit besteht, dass ein Teil des für 2014 prognostizierten Gewinnwachstums schon in diesem Jahr erzielt werden kann. Ich freue mich zudem, an dieser Stelle nochmals unser Vorhaben zu bekräftigen, unser Aktienrückkaufprogramm über 800 Millionen Schweizer Franken innerhalb des ursprünglich vorgesehenen Zeitplans abzuschliessen." Bei der Bekanntgabe der Geschäftsergebnisse für 2012 ging Actelion davon aus, dass der Kerngewinn 2013 unter Ausschluss unvorhergesehener Ereignisse...

ACTELION LTD: Actelion mit starken Ergebnissen im ersten Quartal 2013 [Published 4 Traders - Apr 16 2013]

More Content

sort by: Date \| Relevance
Additional macitentan (Opsumit) data in pulmona... [Published Saudi Fransi Capital - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Presscontacts.com - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Yahoo! Finance - May 17 2013]
Actelion Pharmaceuticals Ltd : Additional macit... [Published Investegate - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Best Invest - May 17 2013]
ACTELION LTD : Additional macitentan (Opsumit) ... [Published 4 Traders - May 17 2013]
Actelion Pharmaceuticals Ltd: Additional macite... [Published FinanzNachrichten.de - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Reuters - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published ACN Newswire - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published TD Ameritrade - May 17 2013]
Pulmonary Arterial Hypertension [Published Advance for NPs and PAs - May 08 2013]
Gilead Sciences, Inc. (GILD): The Heart Of The ... [Published InsiderMonkey.com - May 08 2013]
Gilead Shows Some Heart [Published Motley Fool - May 08 2013]
UPDATE 1-Actelion gets go-ahead to continue new... [Published Reuters - May 08 2013]
Actelion Pharmaceuticals Ltd: Actelion provides... [Published FinanzNachrichten.de - May 08 2013]
Actelion provides update on Phase III GRIPHON s... [Published PR inside - May 08 2013]
Ambrisentan Fails in Lung Fibrosis [Published MedPage Today - May 06 2013]
United Therapeutic's Second PAH Stumble Emphasi... [Published Seeking Alpha - Apr 30 2013]
Pulmonary Arterial Hypertension (PAH) Therapeut... [Published PipelineReview - Apr 20 2013]
ACTELION LTD : Ordentliche Generalversammlung v... [Published 4 Traders - Apr 18 2013]
ACTELION LTD: Actelion's Annual General Meeting... [Published 4 Traders - Apr 18 2013]
Actelion Pharmaceuticals Ltd: Actelion's Annual... [Published FinanzNachrichten.de - Apr 18 2013]
Actelion Pharmaceuticals Ltd : Actelion's Annua... [Published Investegate - Apr 18 2013]
Actelion's Annual General Meeting of Shareholde... [Published Best Invest - Apr 18 2013]
Actelion's Annual General Meeting of Shareholde... [Published Benzinga.com - Apr 18 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Yahoo! Finance - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
BB BIOTECH AG : Biotech sector maintains upward... [Published Investegate - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]

Blogs

sort by: Date \| Relevance
Actelion Ltd. Earnings Call Insights: Domestic ... [Published Wall St. Cheat Sheet - Apr 17 2013] Actelion Ltd. ( NASDAQ:ATLN ) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.Domestic InventoryRavi Mehrotra – Credit Suisse : Congratulation on a great quarter. Let me ask the most obvious ...
Discord Among Accord and Acorda Over AMPYRA Bio... [Published FDA Law Blog - Apr 03 2013] By Kurt R. Karst –A recent Complaint filed in the U.S. District Court for the Southern District of Florida by Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd. (collectively, “Accord Healthcare”) against Acorda Therapeutics Inc. (“Acorda”) and H.D. ...
FTC Slams Drugmaker For Withholding Samples [Published Pharmalot - Mar 13 2013] Should a brand-name drugmaker be required to sell samples of its medicine to an aspiring generic rival when its medicine was approved with a Risk Evaluation and Mitigation Strategy? What if the brand-name drugmaker argues that its REMS could be threatened ...
FTC Chimes In On Restricted Distribution and Ge... [Published FDA Law Blog - Mar 12 2013] By Kurt R. Karst –We thought it would only be a matter of time until the Federal Trade Commission (“FTC”) decided to voice its views in a lawsuit filed last September by Actelion Pharmaceuticals Ltd. and Actelion Clinical Research, Inc. (collectively ...
Antitrust Law Must Play Traditional “Magna Cart... [Published FDA Law Blog - Mar 07 2013] By Kurt R. Karst –Earlier ths week, Apotex Corp., Roxane Laboratories, Inc., and Actavis Elizabeth LLC (collectively “Counterclaim Plaintiffs”) filed their opposition to Actelion Pharmaceuticals Ltd.’s and Actelion Clinical Research, Inc.’s (collectively ...

Press Releases

sort by: Date \| Relevance
Research and Markets: Orphan Drugs: Market Envi... [Published Business Wire Health News - Jan 16 2013]